KBP 7072

Drug Profile

KBP 7072

Alternative Names: KBP-7072

Latest Information Update: 13 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator KBP Biosciences
  • Class Antibacterials; Small molecules; Tetracyclines
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Bacterial infections

Most Recent Events

  • 10 Apr 2018 KBP Biosciences plans a global phase II trial in bacterial infections (KBP Biosciences pipeline, April 2018)
  • 04 Oct 2017 Safety and pharmacokinetic data from a phase I trial in healthy volunteers presented at the IDWeek 2017 (IDW-2017)
  • 22 Nov 2016 KBP 7072 receives Fast Track designation for Bacterial infections in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top